Evidence map›Paper›PMID 31661901›Full record

ArticleInternational journal of molecular sciences2019

Cordycepin Enhances Radiosensitivity in Oral Squamous Carcinoma Cells by Inducing Autophagy and Apoptosis Through Cell Cycle Arrest.

Sheng-Yow Ho, Wun-Syuan Wu, Li-Ching Lin, Yuan-Hua Wu, Hui-Wen Chiu, Ya-Ling Yeh, Bu-Miin Huang, Ying-Jan Wang

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Advances in Small Molecular Agents against Oral Cancer.Molecules (Basel, Switzerland) · 2024
    Review
  9. Review
  10. The role and mechanisms of cordycepin in inhibiting cancer cells.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2024
    Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Sheng-Yow HoDepartment of Radiation Oncology, Chi Mei Medical Center, Liouying, Tainan 736, Taiwan. shengho@seed.net.tw.
Wun-Syuan WuDepartment of Environmental and Occupational Health, College of Medicine, National Cheng Kung University, Tainan 704, Taiwan. vovo1215@hotmail.com.
Li-Ching LinDepartment of Radiation Oncology, Chi Mei Medical Center, Tainan 710, Taiwan. liching51@yahoo.com.tw.
Yuan-Hua WuDepartment of Environmental and Occupational Health, College of Medicine, National Cheng Kung University, Tainan 704, Taiwan. wuyh@mail.ncku.edu.tw.
Hui-Wen ChiuGraduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei 110, Taiwan. smile710905@gmail.com.
Ya-Ling YehDepartment of Environmental and Occupational Health, College of Medicine, National Cheng Kung University, Tainan 704, Taiwan. linn7627@hotmail.com.
Bu-Miin HuangDepartment of Cell Biology and Anatomy, College of Medicine, National Cheng Kung University, Tainan 701, Taiwan. bumiin@mail.ncku.edu.tw.
Ying-Jan WangDepartment of Environmental and Occupational Health, College of Medicine, National Cheng Kung University, Tainan 704, Taiwan. yjwang@mail.ncku.edu.tw.
National Cheng Kung University · TWChi Mei Medical Center · TWChina Medical University · TWNational Cheng Kung University Hospital · TWTaipei Medical University-Shuang Ho Hospital · TW

Funding

Ministry of Science and Technology, Taiwan MOST 105-2320-B-006-021Ministry of Science and Technology, Taiwan MOST 105-2320-B-006-028
6 · The paper itself

Abstract

Oral squamous cell carcinoma (OSCC) is one of the most common cancers worldwide and accounts for over 90% of malignant neoplasms of the oral cavity, with a 5-year survival rate of less than 50%. The long-term survival rate of OSCC patients has not markedly improved in recent decades due to its heterogeneous etiology and treatment outcomes. We investigated the anticancer effect of the combination of irradiation (IR) and cordycepin in the treatment of human OSCC cells in vitro. The type of cell death, especially autophagy and apoptosis, and the underlying mechanisms were examined. We found synergistic effects of cordycepin and IR on the viability of human oral cancer cells. The combination of cordycepin and IR treatment induced apoptosis, cell cycle arrest, and autophagic cell death. Furthermore, cordycepin induced S-phase arrest and prolonged G2/M arrest in the cells that received the combination treatment compared with those that received irradiation alone. Combined treatment induced the upregulation of ATG5 and p21 in an autophagy cascade-dependent manner, arrested the cell cycle in the G2/M phase, and repressed cell proliferation. Thus, we conclude that the combination of cordycepin and IR treatment could be a potential therapeutic strategy for OSCC.

Indexed as

Radiation ToleranceAntineoplastic AgentsApoptosisAutophagyAutophagy-Related Protein 5Cell Cycle CheckpointsCell Line, TumorCell ProliferationCell SurvivalCombined Modality TherapyCyclin-Dependent Kinase Inhibitor p21DeoxyadenosinesG2 Phase Cell Cycle CheckpointsHumansMouth NeoplasmsSquamous Cell Carcinoma of Head and NeckAntineoplastic AgentsATG5 protein, humanAutophagy-Related Protein 5CDKN1A protein, humancordycepinCyclin-Dependent Kinase Inhibitor p21Deoxyadenosinesapoptosisautophagycell cyclecordycepinoral squamous cell carcinomaradiation

Identifiers

PMID31661901
PMCPMC6862293
OpenAlexW2982058458

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.